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Abstract
Influenza spreads rapidly to affect 515% of the global population on an annual basis. It is estimated that influenza causes between 
three and five million cases of severe illness and between a quarter and half a million deaths every year. In South Africa during the 
period from 1997 to 2001, influenza and pneumonia combined was one of the top five causes of death for both males and females.1 
Influenza illness causes substantial morbidity and mortality, with healthcare costs and lost productivity due to absenteeism resulting 
in both direct and indirect costs and, ultimately, a formidable economic burden.2 
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Introduction
The general practitioner’s role in flu prevention and treatment extends 
much further than simply providing a convenient and accessible cold-
chain outlet of flu vaccines and offering symptomatic treatment. Early 
flu patients present often to the pharmacists or clinic nurse first and 
these health care workers should be educated to refer patients to the 
family practitioner for early antiviral treatment. Early antiviral treatment 
(within 48 hours) can be given to patients with flu to reduce secondary 
complications, reduce the spread of influenza to high-risk patients and 
to shorten the duration of illness. It can also reduce the severity of flu, 
even in vaccinated individuals who have developed flu. It can also be 
given as post-exposure prophylaxis in high-risk patients.
More about the influenza virus
The influenza virus, which causes influenza, is a single-stranded, 
helical-shaped, RNA virus that belongs to the orthomyxoviridae 
family. Nuclear material of the virus determines the antigen types of 
A, B and C. The influenza virus has surface antigens haemagglutinin 
(H) for viral attachment to host cells, and neuraminidase (N) for viral 
penetration in host cells. These H and N surface antigens denote the 
different subtypes. Influenza A tends to cause moderate to severe 
illness in all age groups, and can infect humans and animals, including 
birds. Influenza B causes milder disease only in humans, primarily 
in children. Influenza C has rarely been reported to affect humans. 
The problem with the influenza virus is that it undergoes antigenic 
drift, which means that new strains evolve that are related to those 
circulating during previous epidemics. Antigenic shift refers to the 
emergence of a new virus that possesses novel haemagglutinins with/
or a novel neuraminidase. This virus is distinct from earlier viruses and 
arises through mutations.3,4,5  
Influenza is a highly infectious disease that primarily attacks the 
respiratory system. It is transmitted by inhalation of microdroplets,3 
after which the virus attaches to and penetrates the respiratory 
epithelial cells in the trachea and bronchi where viral replication occurs 
to destroy the host cell.4
Symptoms and signs
The symptoms of influenza begin after an incubation period of between 
one and four days, and resemble the common cold at first with a 
sore throat and rhinorrhoea. Sudden onset chills, fever, malaise, 
generalised body aches and pains signify typical influenza in adults. 
Associated symptoms include photophobia and headache. The 
respiratory symptoms tend to progress from a scratchy sore throat, 
substernal burning and non-productive cough to persistent, raspy and 
productive cough. The cough, weakness, sweating and fatigue can 
last for a couple of weeks. Pneumonia, a complication of influenza, 
is suggested by worsening cough with bloody or purulent sputum, or 
dyspnoea.6 Influenza in young children is difficult to diagnose as it is 
often indistinguishable from other respiratory infections because there 
are no unique symptoms specific to influenza.7 Children can, however, 
present with prominent nausea, vomiting and abdominal pain during 
an episode of influenza.6 The influenza virus is found to circulate with 
the respiratory syncytial virus (RSV), and thus children who present 
with influenza-like symptoms may have more than one virus present 
simultaneously. The complications that arise from influenza may 
be a consequence of the influenza or due to secondary bacterial 
infections. The complications include febrile convulsions, bronchiolitis, 
pneumonia, croup, acute otitis media and encephalitis. Influenza is 
highly contagious in children due to a short viral replication cycle and 
prolonged viral shedding.7 See Table I for flu and cold symptoms.
Vaccination
The influenza vaccination is an important factor in combating influenza 
and is advocated for the primary prevention of influenza in people 
who have not been infected with the strain of influenza currently in 
circulation. The vaccines that are currently available in South Africa 
are all inactivated vaccines and they consist of 1) whole virus vaccines 
prepared from formalin-inactivated whole virions grown in embryonated 
chicken eggs, 2) split vaccines produced the same way as whole virus 
vaccines, but the virus particles are disrupted using detergents, and 3) 
subunit vaccines that consist of purified HA and NA proteins with the 
rest of the viral components removed.5
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A fever of more than  
39°C is more likely 
to be flu
Rare
If the patient’s 
temperature is 
normal it is more 







Coughs Common and severe







“I cannot go to work”
Mild
Causes 
absenteeism: “I do 
not want to go to 
work”
Speed of onset Sudden Gradual
Table I: Flu and cold symptoms
Adapted from www.fluworld.com
A Cochrane review of vaccination against influenza in healthy adults 
failed to demonstrate a beneficial effect with regards to reducing the 
spread of the virus, and showed limited effects on reducing working 
days lost, morbidity and hospitalisations. The authors, therefore, 
concluded that routine vaccination of healthy adults should not be 
advocated based on current evidence. However, in the elderly, 
especially those that are deemed high risk, vaccinations help to reduce 
the risk of being hospitalised for complications such as pneumonia.8,9,10 
Another Cochrane review of the influenza vaccine in healthy children 
showed little evidence for routine vaccination in this group. Some of 
the studies may have indicated a decrease in acute otitis media and 
absenteeism from school. The authors concluded that further studies 
are required to evaluate the effects of the vaccine with regards to 
efficacy and other mentioned end-points. From this information it can 
be seen that vaccination should be limited to those in the high-risk 
group.11 
High-risk groups
•  Individuals (adults and children) with chronic medical conditions 
such as pulmonary, cardiac, renal and metabolic diseases such as 
diabetes mellitus. Vaccinations of diabetics results in a reduction in 
hospitalisations for reasons of diabetic control.12 
•  Immunosuppressed adults, including those with HIV infection with 
CD4 counts between 200 and 500 cells/µl.13 It has been shown that 
the influenza vaccine is safe in HIV-infected children, therefore its 
annual use should be advocated.14 Immunosuppresion includes 
patients with asplenia and splenic dysfunction.
•  Inhabitants of chronic care and rehabilitation institutions, as well as 
old age homes.
•  Healthcare personnel responsible for the care of the above-
mentioned patients.
• Family members of the above-mentioned patients.
• All people over the age of 65 years.
•  Women who will be in their second and third trimesters of 
pregnancy during the influenza season. Immunisation at any stage 
of pregnancy is recommended for women with chronic medical 
conditions. 
• Any individuals who wish to protect themselves.  
• Children on long-term aspirin therapy.5,13 
Patients with HIV
Patients infected with HIV have a much higher influenza-attributable 
mortality rate than the general population and the hospitalisation rates 
are similar to those of other high-risk groups. Thus annual vaccination 
is important in these patients. There are no long-term effects on the 
CD4 count, HIV RNA levels or progression to AIDS in those patients 
who use the vaccine, thus healthcare professionals should not hesitate 
to vaccinate this group of high-risk patients to prevent complications. 
The live attenuated form of the influenza vaccine is contraindicated in 
HIV-positive patients.15 
Dosages for each vaccine should be administered as indicated by the 
manufacturer guidelines and it should be noted that children below 
the age of eight years who have previously not been vaccinated need 
a second dose four weeks apart. Vaccines should be administered 
timeously, as a protective antibody response takes about two weeks 
to mount. The vaccine is contraindicated in people with an allergy to 
eggs and should also preferably be avoided during the first trimester 
of pregnancy and during a febrile illness.13 Adverse effects of the 
vaccine are minimal, and include pain, redness and swelling at the site 
of injection, fever and a rash that may last a day or two. Vaccines are 
extremely safe and hypersensitivity reactions are rare.5,12,16 
The vaccines to be used in the 2008 season (southern hemisphere 
winter) should contain the following strains of influenza virus:
• A/Solomon Islands/3/2006 (H1N1)-like virus
• A/Brisbane/10/2007 (H3N2)- like virus
• B/Florida/4/2006 – like virus2
Studies have shown that there are four factors that influence why 
patients remain unvaccinated. These are concern regarding side 
effects (i.e. believing that the vaccine causes influenza), lack of 
concern that the illness has any significance, feeling impervious to 
influenza and lack of healthcare provider directive. It is thus imperative 
that pharmacists be proactive and encourage especially high-risk 
patients to be vaccinated.17 
Post-exposure prophylaxis and treatment
Treatment of influenza is chiefly symptomatic, with currently utilised 
modalities including rest, hydration and occasional anti-pyretics. It 
should be noted that the use of aspirin is not advised in children during 
a viral illness. Oseltamivir is an oral antiviral agent (neuraminidase 
inhibitor) and is effective against influenza A and B. It can be used in 
the treatment of acute influenza to shorten the duration of disease, 
to reduce the severity and to prevent other complications such as 
pneumonia. It is also effective for post-exposure prophylaxis. It is 
registered for the treatment of patients above one year of age provided 
it is started within 48 hours of the commencement of symptoms. 
Oseltamivir is also recommended for post-exposure prophylaxis in 
high-risk people who have had contact with another person who 
exhibits influenza-like symptoms and who have not been adequately 
protected by vaccination. Once again, prophylaxis needs to be 
commenced within 48 hours. It should be taken after meals to reduce 
nausea and vomiting.  
Zanamavir is another neuraminidase inhibitor and inhibits a wide range 
of influenza viruses type A and B. It is administered through an inhaler 
and advocated for the treatment of patients above 12 years of age.12,18
Amantadine and rimantadine specifically inhibit the replication of the 
influenza A virus by blocking the proton pump of the M2 protein in the 
virus, but has no activity against influenza B. Both these antivirals are 
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relatively effective in the prophylaxis and treatment of influenza A. 
However, a Cochrane review recently indicated that these two antivirals 
should be kept for emergency situations when all other measures have 
failed. The NICE (National Institute for Clinical Excellence) guidelines 
recommended that amantadine should not be used for seasonal or 
post-exposure prophylaxis. The adverse effects of amantadine include 
light-headedness, hallucinations, insomnia, dizziness, headache and 
falls, particularly in the elderly. Drug resistance emerges rapidly with 
the use of amantadine. Rimantadine, not currently available in South 
Africa, is not routinely recommended due to its extensive neurological 
adverse effects, particularly in the elderly.19,20 
Box 1: Summary of flu prevention, prophylaxis and treatment
Flu vaccination
• All people over the age of 65 years
• Individuals with chronic medical conditions
• Immunosuppressed adults and children
• Inhabitants of chronic care institutions
• Healthcare personnel treating high-risk people
• Family members of high-risk people
• Pregnant women
• Any individuals who wish to protect themselves
• Children on long-term aspirin therapy
Antiviral therapy
• Patients who present early with flu
• Any patient with acute flu (to reduce duration, severity and spreading) 
• High-risk individuals with flu (to reduce duration and severity)
• High-risk patients exposed to flu
Conclusion 
Influenza can be a devastating disease. However, timeous vaccination 
of the afore-mentioned groups will help to combat the complications 
produced by this disease. Alternative strategies for prevention and 
treatment exist but effectiveness, cost and side-effect profiles need to 
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